Browse MEN1

Summary
SymbolMEN1
Namemultiple endocrine neoplasia I
Aliases menin; MEAI
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Note=Concentrated in nuclear body-like structures. Relocates to the nuclear matrix upon gamma irradiation.
Domain PF05053 Menin
Function

Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates HOXC8 and HOXC6 gene expression. May be involved in normal hematopoiesis through the activation of HOXA9 expression (By similarity). May be involved in DNA repair.

> Gene Ontology
 
Biological Process GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001678 cellular glucose homeostasis
GO:0001890 placenta development
GO:0001893 maternal placenta development
GO:0001933 negative regulation of protein phosphorylation
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0002067 glandular epithelial cell differentiation
GO:0002076 osteoblast development
GO:0003309 type B pancreatic cell differentiation
GO:0006469 negative regulation of protein kinase activity
GO:0006479 protein methylation
GO:0007162 negative regulation of cell adhesion
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007254 JNK cascade
GO:0007565 female pregnancy
GO:0008213 protein alkylation
GO:0009314 response to radiation
GO:0009411 response to UV
GO:0009416 response to light stimulus
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0010212 response to ionizing radiation
GO:0010332 response to gamma radiation
GO:0010810 regulation of cell-substrate adhesion
GO:0010812 negative regulation of cell-substrate adhesion
GO:0010948 negative regulation of cell cycle process
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0018022 peptidyl-lysine methylation
GO:0018205 peptidyl-lysine modification
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030511 positive regulation of transforming growth factor beta receptor signaling pathway
GO:0031016 pancreas development
GO:0031018 endocrine pancreas development
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031589 cell-substrate adhesion
GO:0032092 positive regulation of protein binding
GO:0032259 methylation
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032873 negative regulation of stress-activated MAPK cascade
GO:0032924 activin receptor signaling pathway
GO:0032925 regulation of activin receptor signaling pathway
GO:0033500 carbohydrate homeostasis
GO:0033673 negative regulation of kinase activity
GO:0034284 response to monosaccharide
GO:0034968 histone lysine methylation
GO:0035270 endocrine system development
GO:0035883 enteroendocrine cell differentiation
GO:0042326 negative regulation of phosphorylation
GO:0042593 glucose homeostasis
GO:0043393 regulation of protein binding
GO:0043409 negative regulation of MAPK cascade
GO:0043414 macromolecule methylation
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0043434 response to peptide hormone
GO:0044342 type B pancreatic cell proliferation
GO:0044706 multi-multicellular organism process
GO:0044770 cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045667 regulation of osteoblast differentiation
GO:0045668 negative regulation of osteoblast differentiation
GO:0045736 negative regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0045786 negative regulation of cell cycle
GO:0046328 regulation of JNK cascade
GO:0046329 negative regulation of JNK cascade
GO:0046697 decidualization
GO:0048608 reproductive structure development
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0051052 regulation of DNA metabolic process
GO:0051053 negative regulation of DNA metabolic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051348 negative regulation of transferase activity
GO:0051403 stress-activated MAPK cascade
GO:0051972 regulation of telomerase activity
GO:0051974 negative regulation of telomerase activity
GO:0060135 maternal process involved in female pregnancy
GO:0061458 reproductive system development
GO:0061469 regulation of type B pancreatic cell proliferation
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070303 negative regulation of stress-activated protein kinase signaling cascade
GO:0071322 cellular response to carbohydrate stimulus
GO:0071326 cellular response to monosaccharide stimulus
GO:0071331 cellular response to hexose stimulus
GO:0071333 cellular response to glucose stimulus
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071897 DNA biosynthetic process
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1902532 negative regulation of intracellular signal transduction
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1903844 regulation of cellular response to transforming growth factor beta stimulus
GO:1903846 positive regulation of cellular response to transforming growth factor beta stimulus
GO:1904029 regulation of cyclin-dependent protein kinase activity
GO:1904030 negative regulation of cyclin-dependent protein kinase activity
GO:1904837 beta-catenin-TCF complex assembly
GO:2000278 regulation of DNA biosynthetic process
GO:2000279 negative regulation of DNA biosynthetic process
Molecular Function GO:0000217 DNA secondary structure binding
GO:0000400 four-way junction DNA binding
GO:0000403 Y-form DNA binding
GO:0003682 chromatin binding
GO:0008168 methyltransferase activity
GO:0008170 N-methyltransferase activity
GO:0008276 protein methyltransferase activity
GO:0008757 S-adenosylmethionine-dependent methyltransferase activity
GO:0016278 lysine N-methyltransferase activity
GO:0016279 protein-lysine N-methyltransferase activity
GO:0016741 transferase activity, transferring one-carbon groups
GO:0018024 histone-lysine N-methyltransferase activity
GO:0030674 protein binding, bridging
GO:0042054 histone methyltransferase activity
GO:0043566 structure-specific DNA binding
GO:0046332 SMAD binding
GO:0047485 protein N-terminus binding
GO:0060090 binding, bridging
GO:0070412 R-SMAD binding
Cellular Component GO:0000781 chromosome, telomeric region
GO:0000784 nuclear chromosome, telomeric region
GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0016363 nuclear matrix
GO:0032153 cell division site
GO:0032154 cleavage furrow
GO:0032155 cell division site part
GO:0034399 nuclear periphery
GO:0034708 methyltransferase complex
GO:0035097 histone methyltransferase complex
GO:0044454 nuclear chromosome part
GO:0097610 cell surface furrow
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3769402: Deactivation of the beta-catenin transactivating complex
R-HSA-201722: Formation of the beta-catenin
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-195258: RHO GTPase Effectors
R-HSA-5626467: RHO GTPases activate IQGAPs
R-HSA-2173796: SMAD2/SMAD3
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
R-HSA-2173793: Transcriptional activity of SMAD2/SMAD3
Summary
SymbolMEN1
Namemultiple endocrine neoplasia I
Aliases menin; MEAI
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MEN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolMEN1
Namemultiple endocrine neoplasia I
Aliases menin; MEAI
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MEN1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 0.96; FDR: 0.007980 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMEN1
Namemultiple endocrine neoplasia I
Aliases menin; MEAI
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MEN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1820.427
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1210.947
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.220.878
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3450.274
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4070.824
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.270.91
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0580.853
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1380.919
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0250.987
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2760.835
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6250.738
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0420.515
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MEN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMEN1
Namemultiple endocrine neoplasia I
Aliases menin; MEAI
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MEN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMEN1
Namemultiple endocrine neoplasia I
Aliases menin; MEAI
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MEN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MEN1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMEN1
Namemultiple endocrine neoplasia I
Aliases menin; MEAI
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MEN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMEN1
Namemultiple endocrine neoplasia I
Aliases menin; MEAI
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MEN1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMEN1
Namemultiple endocrine neoplasia I
Aliases menin; MEAI
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MEN1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMEN1
Namemultiple endocrine neoplasia I
Aliases menin; MEAI
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MEN1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.